Home Newsfeeds Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

byBenzinga Newsdesk

December 22, 2022

1 minute read

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

Needham Maintains Buy on Rigetti Computing, Lowers Price Target to $3

By Benzinga Newsdesk

November 15, 7:56 AM

Needham analyst Quinn Bolton maintains Rigetti Computing (NASDAQ:RGTI) with a Buy and lowers the price target from $11 to $3.

RGTI

Analyst Touts ‘Key Underlying Improvements’ For HEXO Despite Q1 Revenue Drop

By Jelena Martinovic

December 16, 12:09 PM

Hexo Corp. (NASDAQ: HEXO) reported a 29% year-over-year and 16% sequential decrease in net revenue to CA$ 35.8 million ($26.3 million) in the first quarter of fiscal 2023.

HEXO

Why Rivian Automotive Stock Is Moving Lower

By Erica Kollmann

January 17, 12:00 PM

Deutsche Bank noted that its downgrade of Rivian is based in part on an expected volume guidance of only 65,000 units resulting from factory shutdowns and a slow ramp up which could result in heavy losses through the third quarter of 2024.

RIVN

Which Video Games Generate The Most Money For Electronic Arts? EA Driving 73% Of Revenue From Games-As-A-Service

By Benzinga Gaming

November 28, 4:29 PM

Electronic Arts (NASDAQ: EA), the company that owns "FIFA," "Battlefield" and "Need For Speed," announced that 73

Oppenheimer Downgrades Fate Therapeutics to Perform

Related Posts

Needham Maintains Buy on Rigetti Computing, Lowers Price Target to $3

Analyst Touts ‘Key Underlying Improvements’ For HEXO Despite Q1 Revenue Drop

Why Rivian Automotive Stock Is Moving Lower

Which Video Games Generate The Most Money For Electronic Arts? EA Driving 73% Of Revenue From Games-As-A-Service